Compare Capital One Financial Corp. (COF) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Cytokinetics Inc — how do they compare? Capital One Financial Corp. trades at $207 (market cap $126.46B), while Cytokinetics Inc trades at $82.6 (market cap $11.12B). The key difference: Capital One Financial Corp. is far larger — about 11.4× Cytokinetics Inc's market cap, and Capital One Financial Corp. pays a 1.56% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| COF | CYTK | |
|---|---|---|
Market Cap | $126.46B | $11.12B |
Sector | Financials | Technology |
52-Week High | $257.94 | $87.26 |
52-Week Low | $176.10 | $33.23 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $203.02, up 0.74% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but strong revenue growth to $53.43B in 2025. Analyst consensus remains positive with a $252.40 price target and 62.5% buy ratings, while the Discover integration presents significant expansion opportunities amid credit risk concerns.
COF offers potential upside from current levels with Wall Street optimism around the Discover acquisition, though investors face headwinds from rising delinquencies and margin compression. The stock's valuation at 62.44 P/E appears elevated relative to modest ROE of 3.34%, requiring careful monitoring of integration execution and credit quality trends.
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
